Q-omics provides the consensus-scored ELK2AP profile across patient tissues and cancer cell-line models. ELK2AP expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ELK2AP is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, ELK2AP RNA expression shows 6,100 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, THCA, and STAD as cancer lineages where ELK2AP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELK2AP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELK2AP survival associations across molecular data types. ELK2AP RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELK2AP RNA expression–survival associations across cancer types. High ELK2AP expression shows unfavorable associations in UCS, SKCM, LUSC, LAML and PRAD, but favorable associations in BRCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ELK2AP RNA expression.
This table summarizes ELK2AP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELK2AP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELK2AP shows lower tumor expression in THCA and higher tumor expression in BRCA and LUAD. The THCA box plot shows higher ELK2AP RNA expression in normal versus tumor tissue (log2 FC = −0.052, t-test p < 0.001).
This table shows molecular features associated with ELK2AP in patient tissues and cancer cell lines. In patient samples, ELK2AP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ELK2AP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
